Acumapimod is primarily investigated for its potential therapeutic applications in the treatment of inflammatory diseases. It functions as a p38 MAP kinase inhibitor, which plays a crucial role in regulating the production of pro-inflammatory cytokines. By inhibiting this pathway, it may help reduce inflammation and alleviate symptoms in conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). Clinical studies have explored its efficacy in managing acute exacerbations of COPD, where it has shown promise in reducing inflammation and improving lung function. Additionally, its anti-inflammatory properties are being studied for potential use in other inflammatory disorders, offering a targeted approach to modulate immune responses.